Search
IRPHI 300 MG, Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 30 |
| Strength (Dosage) | 300 MG |
| Laboratory | PHI |
| Ingredients | Irbesartan |
| Therapeutic class | Antagoniste sélectif des récepteurs de l'angiotensine II |
| ATC code | C09CA04 |
| PPH | $10.05 |
| PPV | $16.09 |
| Refundable | Yes |
| Refund base | $16.09 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | L’irbersartan est indiqué chez l’adulte dans le traitement de l’ hypertension artérielle essentielle. Il est également indiqué dans le traitement de l’atteinte rénale chez les patients adultes hypertendus diabétiques de type 2, dans le cadre de la prise en charge par un médicament antihypertenseur. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications with one or more of the ingredients above
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem